Back

Effect of perceived and objectively-assessed frailty on outcomes in edoxaban-treated patients with atrial fibrillation: data from the ETNA-AF-Europe 4-year follow-up

28 August 2023 (09:15 - 09:50)
Organised by: Logo
Congress Presentation Part of: Atrial fibrillation stroke prevention with oral anticoagulants Oral Anticoagulation ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Associate Professor Stefano Fumagalli

Internal and Specialist Medicine and Geriatric Arrhythmia Unit, Florence (Italy)

6 More presentations in this session

Presentation thumbnail
Impact of proton pump inhibitor on quality of anticoagulant control and outcomes in atrial fibrillation patients treated with an oral anticoagulant in the COOL-AF registry.
Doctor P. Chichareon (Hat Yai, TH)
Abstract Slides Video
Presentation thumbnail
Comparative analysis of oral anticoagulation therapy in Asian patients with atrial fibrillation and end-stage renal disease: a nationwide population-based cohort study
Doctor S. Lee (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Factors associated with delayed treatment initiation of oral anticoagulants among Medicare patients with atrial fibrillation
Doctor X. Luo (Groton, US)
Abstract Slides Video
Presentation thumbnail
Oral anticoagulation among frail patients with atrial fibrillation: assessment of net clinical benefit in a nationwide cohort
Ms M. Soegaard (Aalborg, DK)
Abstract Slides Video
Presentation thumbnail
Relationship between care speciality and atrial fibrillation outcomes in the GARFIELD-AF registry
Doctor C. Camm (Oxford, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Atrial fibrillation stroke prevention with oral anticoagulants

The Event

Event poster

ESC Congress 2023

28 August 2023 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Edoxaban dose, frailty, and outcomes in patients with atrial fibrillation: the ETNA-AF-Europe 4-year follow-up
thumbnail
Congress Presentation
Impact of oral anticoagulants in frail atrial fibrillation patients: a report from an observational registry of european patients
thumbnail
Congress Presentation
Direct oral anticoagulation versus warfarin in atrial fibrillation: a nationwide cohort study of effectiveness and safety among frail patients

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources